Aurobindo Pharma reported a marginal increase of 3% in its net profit to Rs 595 crore for the third quarter, against Rs 578.6 crore in the year-ago period. Revenue from operations stood at Rs 4,336.1 crore, an increase of 11% over the same period last year. Formulation sales in the US registered Rs 1,909.6 crore, compared with Rs 1,745.1 crore in Q3FY17, a growth of 9.4%. The Europe formulation sales stood at Rs 1,171.6 crore, registering a strong growth of 37% on a year-on-year basis. “All our key markets continue to perform well and have shown a healthy growth trend. Considering the one-off US tax charge, the profitability is in-line with our expectations. We continue to invest in enhancing our specialty and complex generics pipeline, for a sustainable growth,” N Govindarajan, MD, said in a statement. While the anti-retro viral (ARV) sales registered Rs 238.9 crore, against Rs 341.9 crore in Q3FY17, the growth market sales was at Rs 250.2, up 33.2%. API sales for thee quarter stood at Rs 765.7 crore, compared with Rs 775.9 crore.